Treatments for Ocular Neovascularization

USPTO granted patent US12599680B1 to 4D Molecular Therapeutics Inc. on April 14, 2026. The patent covers compositions and methods for treating ocular neovascular diseases, particularly wet age-related macular degeneration. The patent contains 24 claims and is classified under A61P 27/02.

This patent grant confers exclusive rights to the assignee for the commercial exploitation of the patented technology in the United States. Third parties seeking to develop or commercialize similar ocular neovascular disease treatments will need to either design around the patent claims or seek licensing from the assignee.